Evoke Pharma, Inc.

As of November 10, 2021, Evoke Pharma, Inc. is considered risky and overvalued based on its financial metrics, with key ratios indicating significant valuation concerns and underperformance compared to peers and the S&P 500.

As of November 10, 2021, Evoke Pharma, Inc. is considered overvalued and risky, with key financial metrics indicating poor performance, including a negative P/E ratio and a year-to-date return of -43.44%, compared to the S&P 500's 2.44% return.

As of June 4, 2025, the technical trend is mildly bearish, driven by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from MACD and KST, with the stock underperforming against the S&P 500.

As of March 2022, the management team of Evoke Pharma, Inc. includes Chairman and Co-Founder Cam Garner, CEO and Founder David Gonyer, and Directors Todd Brady, Ann Rhoads, and Ken Widder.

Evoke Pharma, Inc. is a micro-cap specialty pharmaceutical company focused on developing treatments for gastrointestinal disorders. As of March 2025, it reported net sales of $3 million and a net loss of $1 million, with a market cap of $4.14 million.

As of Jun 18, Evoke Pharma, Inc. has a market capitalization of 4.14 million, categorizing it as a Micro Cap company, with net sales of 11.59 million and a net profit of -5.08 million for the latest four quarters ending in March 2025. As of December 2024, the company's shareholder's funds were 7.04 million, and total assets were 17.52 million.